Deception isn't required for the placebo effect. Studies show that 'open-label' placebos, where patients know they are taking an inert pill, can produce improvements comparable to leading medications. The power of anticipation and ritual alone can alleviate symptoms.

Harvard research shows that "open-label" placebos—pills explicitly labeled as such—can be as effective as leading medications for conditions like IBS. This decouples the placebo effect from deception, highlighting the power of ritual and expectation.

The iconic name 'Viagra' was created for a prostate drug to evoke a "vigorous stream." When Pfizer developed a drug for erectile dysfunction, it repurposed the pre-existing, "banked" name, showing how companies strategically reuse branding assets for a better fit.

The overactive bladder market is chronically underserved not due to a lack of options, but because existing treatments (drugs linked to dementia, expensive implants) are so flawed that 78% of patients refuse them. This massive patient drop-off signals a prime opportunity for safer, more accessible alternatives.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

A genetic diagnostics machine was built to speed up patient diagnosis in hospitals. However, its biggest market turned out to be pharmaceutical companies needing to prove drug efficacy. This highlights how true product-market fit can be discovered accidentally in an adjacent, more lucrative market.

Neuroscientist Andrew Huberman explains that Tadalafil, originally a prostate health drug, improves blood perfusion at low doses (2.5-5mg). A Stanford urologist suggests most men over 40 could benefit from this daily regimen, framing it as a health measure rather than just for erectile dysfunction.

Years before its official FDA approval, Eli Lilly's next-generation weight-loss peptide, Retatrutide, has become a standard tool for bodybuilders. They acquire it from 'research use only' websites to leverage its potent fat-burning and liver-health benefits. This shows a new dynamic where niche communities effectively beta-test drugs at scale before their commercial release.

To get FDA approval, new opioids must undergo Human Abuse Potential (HAP) studies. In these counter-intuitive trials, the goal is to lose. The drug is tested on recreational opioid users to measure its 'liking' score. Success is defined by demonstrating the new drug is significantly less preferable than existing abusable opioids like Oxycodone.